Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

New cancer drug Avastin keeps cancer under control

Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new cancer drug Avastin keeps cancer under control for a significantly longer duration, even when used in a group of elderly patients with advanced colorectal cancer who are too sick to tolerate traditional aggressive chemotherapy.

1 Mar 2005

Angiogenesis inhibitor molecules defend against the development and spread of cancer

Research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) helps explain how a group of angiogenesis inhibitor molecules serve as an important defense mechanism against the development and spread of cancer, offering key insights into why cancerous tumors grow at different rates among different individuals.

15 Feb 2005

Bionomics goes for aggressive strategy in 2005

Australian biotech, Bionomics gave an investor presentation in Melbourne on 2 February 2005 and outlined a bolder, more aggressive strategy. There are many Australian biotech companies with big aspirations.

13 Feb 2005

Experimental drug Revlimid showing promise as treatment for myelodysplastic syndrome (MDS)

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia.

10 Feb 2005

Gene therapy for heart patients with chest pains who do not benefit from other treatments

Individuals with moderate to severe chest pains (angina) who have not found relief from medication may benefit from a new gene therapy approach being used by cardiologists at Rush University Medical Center to grow new blood vessels in the heart.

3 Feb 2005

Painful surgical adhesions may be preventable by taking the COX-2 inhibitor Celebrex

Adhesions – bands of scar tissue that bind together two internal body surfaces – develop in 55 percent to more than 90 percent of patients undergoing surgery, depending on the type of operation. They are part of normal healing, but when surfaces fuse together that shouldn't, serious pain and complications can result.

26 Jan 2005

Schering and Novartis agree on joint commercialization of novel cancer drug

Schering AG, Germany announced today that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and Novartis to maximize the compound's full potential.

25 Jan 2005

Research leads to new antiangiogenic drugs

Scientists have uncovered critical information that may lead to an urgently needed method for effective monitoring of antiangiogenic cancer therapies.

17 Jan 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

20 Dec 2004

Landmark revascularization procedure

The People's Hospital of Beijing University performed a combined revascularization procedure utilizing beating heart bypass surgery, along with transmyocardial revascularization and stem cell implantation.

13 Dec 2004

Model may explain how alcohol stimulates tumor growth

The investigators found that compared to the saline control group, the embryos exposed to ethanol experienced increases in tumor size, tumor blood vessel density, cancer cell infiltration of blood vessels, and VEGF levels.

13 Dec 2004

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

Research provides more evidence of communication between developing nerves and blood vessels

In a developing embryo, the growth of nerves cannot outpace the establishment of life-giving blood vessels. Now, researchers have found that a protein intimately involved in blood vessel patterning actually belongs to a family of proteins known to guide neural development.

18 Nov 2004

Protein important to nerve development serves the dual purpose of stimulating the growth of blood vessels

The discovery opens the possibility that blood vessel growth (angiogenesis) one day may be induced, or stymied, for therapeutic use against heart disease, cancer, and other illnesses, according to Dean Y. Li, M.D., Ph.D., associate professor of internal medicine in the U of U School of Medicine's Division of Cardiology.

1 Nov 2004

Potential new treatment strategy against metastatic cancer cells

A team of scientists at The Scripps Research Institute has identified a potential treatment strategy against metastatic cancer cells that has never been tried before.

25 Oct 2004

University of Cambridge executes exclusive patent licences and collaborative research and development agreement with Gene Networks International

The University of Cambridge has entered into two licence agreements with Gene Networks International (GNI), granting exclusive rights to Cambridge's intellectual property related to angiogenesis (the growth of new blood vessels) and inflammation that may have implications in the identification of new drug targets for a range of diseases.

13 Oct 2004

Researchers stimulate the body to repair tissue damaged by peripheral arterial obstructive disease

Duke University Medical Center researchers have shown that they can stimulate the body to produce its own naturally occurring growth factors to promote blood vessel growth into tissue damaged by peripheral arterial obstructive disease (PAOD).